Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Huntington's disease.

Marcy E MacDonald1, Silvia Gines, James F Gusella

  • 1Molecular Neurogenetics Unit, Center for Human Genetics Research, Massachusetts General Hospital, Charlestown, MA 02129, USA. macdonam@helix.mgh.harvard.edu

Neuromolecular Medicine
|October 7, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

WWOX contributes to DNA damage, but not somatic instability in Huntington's disease.

bioRxiv : the preprint server for biology·2026
Same author

TRACE: Open-source software for quantifying somatic variation of tandem repeats by capillary electrophoresis.

Journal of Huntington's disease·2026
Same author

Functional Ca<sup>2+</sup>-permeable AMPA receptors in hippocampal astrocytes mediate calcium signaling in vitro.

Scientific reports·2026
Same author

Huntington's disease LIG1 modifier variant increases ligase fidelity and suppresses somatic CAG repeat expansion.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

TRACE: Open-Source Software for Quantifying Somatic Variation of Tandem Repeats by Capillary Electrophoresis.

bioRxiv : the preprint server for biology·2026
Same author

MSH3 is a genetic modifier of somatic repeat instability in X-linked dystonia parkinsonism.

American journal of human genetics·2025
Same journal

Near‑Infrared Photobiomodulation in White‑Matter Disease: From Microglial States to Measurable Endpoints.

Neuromolecular medicine·2026
Same journal

<sup>64</sup>Cu Hypoxia Imaging Radiotracer Targeting the Human Copper Transporter.

Neuromolecular medicine·2026
Same journal

Curculigoside Alleviates CSDS-induced Depressive-like Behavior by Modulating Pyramidal Neuron Excitability and Synaptic Transmission.

Neuromolecular medicine·2026
Same journal

Association of Cathepsin Proteins with Alzheimer's Disease Risk: An Integrated Observational and Genetic Analysis.

Neuromolecular medicine·2026
Same journal

Single-cell Transcriptomics Reveals that the SORBS1/FBXO22/BAG3 Axis Drives Astrocyte Senescence via Calcium Signaling and Affects Alzheimer's Disease-Related Neuronal Damage.

Neuromolecular medicine·2026
Same journal

Subgroup-Specific Associations of GRIA Genes Encoding AMPA Glutamate Receptor Subunits with Patient Survival in Medulloblastoma.

Neuromolecular medicine·2026
See all related articles

Huntington's disease (HD) research identifies an inherited gene expansion as the cause. Studies are developing therapies by examining disease mechanisms and testing potential drugs in mouse models.

Area of Science:

  • Neuroscience
  • Genetics
  • Pharmacology

Background:

  • Huntington's disease (HD) is a neurodegenerative disorder.
  • The primary cause is an inherited unstable CAG expansion in the 4p16.3 gene, leading to a lengthened polyglutamine segment in huntingtin protein.

Purpose of the Study:

  • To understand the root cause and early mechanisms of Huntington's disease.
  • To identify and develop effective therapeutic agents for HD.
  • To uncover new biological insights into HD pathogenesis.

Main Methods:

  • Molecular genetics to identify the disease-causing gene expansion.
  • Studies in HD patients and genetic HD model systems.
  • Biochemical, cellular, and whole-organism assays to identify disease-modifying genes and drug candidates.

Related Experiment Videos

  • Testing in genetic and phenotypic HD mouse models.

    • Main Results:

    • The disease trigger, an unstable CAG expansion in the HD gene, has been identified.
    • Research is elucidating the trigger mechanism and early disease development.
    • Potential disease-modifying genes and candidate drugs are emerging from various assays.

    Conclusions:

    • Understanding the genetic basis and early molecular events is crucial for HD therapy development.
    • HD mouse models are valuable tools for dissecting disease stages and prioritizing therapeutic strategies.
    • Prioritizing drug candidates through rigorous testing in model systems enhances the likelihood of success in clinical trials for Huntington's disease patients.